ME VS AZN Stock Comparison

Performance

ME
10/100

ME returned -75.03% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

AZN
100/100

AZN returned 6.03% in the last 12 months. Based on SPY's performance of -21.20%, its performance is above average giving it a score of 100 of 100.

Technicals

ME
36/100

ME receives a 35 of 100 based on 14 indicators. 4 are bullish, 8 are bearish.

AZN
11/100

AZN receives a 10 of 100 based on 14 indicators. 1 are bullish, 12 are bearish.

Earnings

ME
10/100

ME has missed earnings 5 times in the last 20 quarters.

AZN
56/100

AZN has missed earnings 3 times in the last 20 quarters.

Profit

ME
10/100

Out of the last 14 quarters, ME has had 0 profitable quarters and has increased their profits year over year on 0 of them.

AZN
77/100

Out of the last 20 quarters, AZN has had 18 profitable quarters and has increased their profits year over year on 9 of them.

Volatility

ME
45/100

ME has had a lower than average amount of volatility over the last 12 months giving it a score of 45 of 100.

AZN
48/100

AZN has had a lower than average amount of volatility over the last 12 months giving it a score of 47 of 100.

Analyst Price Targets

ME

"Analyst Price Targets" not found for ME

AZN
85/100

5 analysts offer 12-month price targets for AZN. Together, they have an average target of 80.5, the most optimistic target put AZN at 82 within 12-months and the most pessimistic has AZN at 79.

Sentiment

ME

"Sentiment" not found for ME

AZN
70/100

AZN had a bullish sentiment score of 70.02% across Twitter and StockTwits over the last 12 months. It had an average of 101.58 posts, 140.17 comments, and 324.32 likes per day.

All score calculations are broken down here to help you make more informed investing decisions

23andMe Holding Co. Class A Common Stock Summary

Nasdaq / ME

Healthcare

Medical - Diagnostics & Research

23andMe Holding Co. operates as a consumer genetics testing company. It operates through two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications based on genetic testing of a saliva sample through its spit kit. The Therapeutics segment focuses on the drug development; and discovery and development of novel therapies to improve patient lives across various therapeutic areas, including oncology, respiratory, and cardiovascular diseases, as well as offers out-licensing of intellectual property associated with identified drug targets related to drug candidates under clinical development. It has a collaboration agreement with GlaxoSmithKline Intellectual Property (No.3) Limited to leverage genetic insights to validate, develop, and commercialize drugs. The company was founded in 2006 and is headquartered in South San Francisco, California.

AstraZeneca PLC Summary

Nasdaq / AZN

Healthcare

Drug Manufacturers - General

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Power up your portfolio